APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Neurological Disorder Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neurological Disorder Drugs Market Outlook and Growth Opportunities 2026

Report ID 174016580420 December 2025193 pages

Choose your research edition.

Industry ResearchNeurological Disorder Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurological Disorder Drugs Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Neurological Disorder Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurological Disorder Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurological Disorder Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neurological Disorder Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neurological Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neurological Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neurological Disorder Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neurological Disorder Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neurological Disorder Drugs market include Boehringer Ingelheim, Teva Pharmaceutical, AstraZeneca, Bayer, GlaxoSmithKline, Merck & Co. and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Neurological Disorder Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neurological Disorder Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neurological Disorder Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Neurological Disorder Drugs market.

Neurological Disorder Drugs Segment by Company

Boehringer Ingelheim

Teva Pharmaceutical

AstraZeneca

Bayer

GlaxoSmithKline

Merck & Co.

Novartis

Neurological Disorder Drugs Segment by Type

Analgesics

Anticoagulants

Antipsychotic

Hypnotic & Sedative

Others

Neurological Disorder Drugs Segment by Application

Hospital

Clinic

Neurological Disorder Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neurological Disorder Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Neurological Disorder Drugs key companies, revenue, market share, and recent developments.

3. To split the Neurological Disorder Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Neurological Disorder Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neurological Disorder Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Neurological Disorder Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurological Disorder Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurological Disorder Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurological Disorder Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurological Disorder Drugs industry.

Chapter 3: Detailed analysis of Neurological Disorder Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Neurological Disorder Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Neurological Disorder Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neurological Disorder Drugs Industry Trends Table 2. Neurological Disorder Drugs Industry Drivers Table 3. Neurological Disorder Drugs Industry Opportunities and Challenges Table 4. Neurological Disorder Drugs Industry Restraints Table 5. Global Neurological Disorder Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neurological Disorder Drugs Revenue Share by Company (2021-2026) Table 7. Global Neurological Disorder Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Neurological Disorder Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Neurological Disorder Drugs Company, Product Type & Application Table 10. Global Neurological Disorder Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Neurological Disorder Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Analgesics Table 15. Significant Companies of Anticoagulants Table 16. Significant Companies of Antipsychotic Table 17. Significant Companies of Hypnotic & Sedative Table 18. Significant Companies of Others Table 19. Global Neurological Disorder Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Neurological Disorder Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Neurological Disorder Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Neurological Disorder Drugs Sales Value Share by Type (2021-2026) Table 23. Global Neurological Disorder Drugs Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Clinic Table 26. Global Neurological Disorder Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neurological Disorder Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Neurological Disorder Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Neurological Disorder Drugs Sales Value Share by Application (2021-2026) Table 30. Global Neurological Disorder Drugs Sales Value Share by Application (2027-2032) Table 31. Global Neurological Disorder Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Neurological Disorder Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Neurological Disorder Drugs Sales Value Share by Region (2021-2026) Table 34. Global Neurological Disorder Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Neurological Disorder Drugs Sales Value Share by Region (2027-2032) Table 36. Global Neurological Disorder Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Neurological Disorder Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Neurological Disorder Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Neurological Disorder Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Neurological Disorder Drugs Sales Value Market Share by Country (2027-2032) Table 41. Boehringer Ingelheim Company Information Table 42. Boehringer Ingelheim Business Overview Table 43. Boehringer Ingelheim Neurological Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Boehringer Ingelheim Neurological Disorder Drugs Product Portfolio Table 45. Boehringer Ingelheim Recent Development Table 46. Teva Pharmaceutical Company Information Table 47. Teva Pharmaceutical Business Overview Table 48. Teva Pharmaceutical Neurological Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Teva Pharmaceutical Neurological Disorder Drugs Product Portfolio Table 50. Teva Pharmaceutical Recent Development Table 51. AstraZeneca Company Information Table 52. AstraZeneca Business Overview Table 53. AstraZeneca Neurological Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. AstraZeneca Neurological Disorder Drugs Product Portfolio Table 55. AstraZeneca Recent Development Table 56. Bayer Company Information Table 57. Bayer Business Overview Table 58. Bayer Neurological Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Bayer Neurological Disorder Drugs Product Portfolio Table 60. Bayer Recent Development Table 61. GlaxoSmithKline Company Information Table 62. GlaxoSmithKline Business Overview Table 63. GlaxoSmithKline Neurological Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. GlaxoSmithKline Neurological Disorder Drugs Product Portfolio Table 65. GlaxoSmithKline Recent Development Table 66. Merck & Co. Company Information Table 67. Merck & Co. Business Overview Table 68. Merck & Co. Neurological Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Merck & Co. Neurological Disorder Drugs Product Portfolio Table 70. Merck & Co. Recent Development Table 71. Novartis Company Information Table 72. Novartis Business Overview Table 73. Novartis Neurological Disorder Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Novartis Neurological Disorder Drugs Product Portfolio Table 75. Novartis Recent Development Table 76. Research Programs/Design for This Report Table 77. Authors List of This Report Table 78. Secondary Sources Table 79. Primary Sources List of Figures Figure 1. Neurological Disorder Drugs Product Image Figure 2. Global Neurological Disorder Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neurological Disorder Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Neurological Disorder Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Analgesics Image Figure 8. Anticoagulants Image Figure 9. Antipsychotic Image Figure 10. Hypnotic & Sedative Image Figure 11. Others Image Figure 12. Global Neurological Disorder Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Neurological Disorder Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Neurological Disorder Drugs Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Clinic Image Figure 17. Global Neurological Disorder Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Neurological Disorder Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Neurological Disorder Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Neurological Disorder Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Neurological Disorder Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Neurological Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Neurological Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Neurological Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Neurological Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Neurological Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Neurological Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Neurological Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Neurological Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Neurological Disorder Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Neurological Disorder Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Neurological Disorder Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Analgesics
  • Anticoagulants
  • Antipsychotic
  • Hypnotic & Sedative
  • Others
Applications
  • Hospital
  • Clinic
Companies covered
  • Boehringer Ingelheim
  • Teva Pharmaceutical
  • AstraZeneca
  • Bayer
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neurological Disorder Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neurological Disorder Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Neurological Disorder Drugs Market Dynamics
  1. 2.1 Neurological Disorder Drugs Industry Trends
  2. 2.2 Neurological Disorder Drugs Industry Drivers
  3. 2.3 Neurological Disorder Drugs Industry Opportunities and Challenges
  4. 2.4 Neurological Disorder Drugs Industry Restraints
3 Neurological Disorder Drugs Market by Company
  1. 3.1 Global Neurological Disorder Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Neurological Disorder Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Neurological Disorder Drugs Company Ranking (2024-2026)
  4. 3.4 Global Neurological Disorder Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Neurological Disorder Drugs Company Product Type and Application
  6. 3.6 Global Neurological Disorder Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Neurological Disorder Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Neurological Disorder Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Neurological Disorder Drugs Market by Type
  1. 4.1 Neurological Disorder Drugs Type Introduction
  2. 4.1.1 Analgesics
  3. 4.1.2 Anticoagulants
  4. 4.1.3 Antipsychotic
  5. 4.1.4 Hypnotic & Sedative
  6. 4.1.5 Others
  7. 4.2 Global Neurological Disorder Drugs Sales Value by Type
  8. 4.2.1 Global Neurological Disorder Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Neurological Disorder Drugs Sales Value by Type (2021-2032)
  10. 4.2.3 Global Neurological Disorder Drugs Sales Value Share by Type (2021-2032)
5 Neurological Disorder Drugs Market by Application
  1. 5.1 Neurological Disorder Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Neurological Disorder Drugs Sales Value by Application
  5. 5.2.1 Global Neurological Disorder Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Neurological Disorder Drugs Sales Value by Application (2021-2032)
  7. 5.2.3 Global Neurological Disorder Drugs Sales Value Share by Application (2021-2032)
6 Neurological Disorder Drugs Regional Value Analysis
  1. 6.1 Global Neurological Disorder Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neurological Disorder Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Neurological Disorder Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Neurological Disorder Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neurological Disorder Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Neurological Disorder Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Neurological Disorder Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Neurological Disorder Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Neurological Disorder Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Neurological Disorder Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Neurological Disorder Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Neurological Disorder Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Neurological Disorder Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Neurological Disorder Drugs Sales Value Share by Country, 2025 VS 2032
7 Neurological Disorder Drugs Country-level Value Analysis
  1. 7.1 Global Neurological Disorder Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neurological Disorder Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Neurological Disorder Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Neurological Disorder Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Neurological Disorder Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Neurological Disorder Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Neurological Disorder Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boehringer Ingelheim
  2. 8.1.1 Boehringer Ingelheim Company Information
  3. 8.1.2 Boehringer Ingelheim Business Overview
  4. 8.1.3 Boehringer Ingelheim Neurological Disorder Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Boehringer Ingelheim Neurological Disorder Drugs Product Portfolio
  6. 8.1.5 Boehringer Ingelheim Recent Developments
  7. 8.2 Teva Pharmaceutical
  8. 8.2.1 Teva Pharmaceutical Company Information
  9. 8.2.2 Teva Pharmaceutical Business Overview
  10. 8.2.3 Teva Pharmaceutical Neurological Disorder Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Neurological Disorder Drugs Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Recent Developments
  13. 8.3 AstraZeneca
  14. 8.3.1 AstraZeneca Company Information
  15. 8.3.2 AstraZeneca Business Overview
  16. 8.3.3 AstraZeneca Neurological Disorder Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Neurological Disorder Drugs Product Portfolio
  18. 8.3.5 AstraZeneca Recent Developments
  19. 8.4 Bayer
  20. 8.4.1 Bayer Company Information
  21. 8.4.2 Bayer Business Overview
  22. 8.4.3 Bayer Neurological Disorder Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bayer Neurological Disorder Drugs Product Portfolio
  24. 8.4.5 Bayer Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Neurological Disorder Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Neurological Disorder Drugs Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Merck & Co.
  32. 8.6.1 Merck & Co. Company Information
  33. 8.6.2 Merck & Co. Business Overview
  34. 8.6.3 Merck & Co. Neurological Disorder Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co. Neurological Disorder Drugs Product Portfolio
  36. 8.6.5 Merck & Co. Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Neurological Disorder Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Neurological Disorder Drugs Product Portfolio
  42. 8.7.5 Novartis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst